Dr. Reza Khan Omarzai, MD

Dr. Omarzai practices at Bon Secours St. Mary's Hospital in Richmond, Virginia, part of Bon Secours Mercy Health.

Dr. Omarzai's NPI, 1821016288, was assigned on July 17, 2006. Dr. Omarzai holds Virginia license 0101057678.

Dr. Omarzai's primary practice is Bon Secours St. Mary's Hospital, at 5801 Bremo Rd, Richmond, VA 23226 in Richmond City. The practice phone is (804) 285-2011.

Dr. Omarzai's primary practice is Bon Secours St. Mary's Hospital in Richmond, Virginia, part of Bon Secours Mercy Health. Dr. Omarzai is also affiliated with Chippenham Hospital. The medical group on file is Virginia Cardiovascular Specialists. Dmand AI also links Dr. Omarzai to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Omarzai practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Omarzai's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Omarzai is licensed in Virginia.

CMS data shows 9,989 Medicare services from Dr. Omarzai across 29 procedure codes in 2024, for 2,018 Medicare patients. Medicare paid $599,924 for them.

CMS counts 2,018 Medicare patients who saw Dr. Omarzai in 2024. The largest group is 75 to 84, with 824 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Omarzai's median patient age at 71, with 54% women.

In 2024, Dr. Omarzai wrote 3,912 Medicare Part D claims for 546 patients. 83% of them were for generic drugs. CMS names the drug for 3,737 of them, across 43 drugs with 11 or more claims each, at $509,534 in total drug cost. In 2023, CMS named 3,448 claims across 45 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Omarzai for performance year 2024, reported as part of a group. Dr. Omarzai accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 516 general payments to Dr. Omarzai from 49 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,704.